Vitamin d3, heat shock proteins, and glutathione for the treatment of chronic inflammation and chronic diseases

Abstract

The present disclosure is directed to co-administration of high dose Vitamin D 3 , heat shock proteins, glutathione, and kits provided for co-administration of these compositions, for the treatment of patients with chronic inflammation and chronic diseases.

What is claimed is: 
     
         1 . A method of treating disease in a patient comprising co-administering to the patient a first composition consisting essentially of Vitamin D 3  and a second composition consisting essentially of heat shock proteins. 
     
     
         2 . The method according to  claim 1 , wherein the first composition consists essentially of about 1,000 IU to about 150,000 IU of Vitamin D 3 . 
     
     
         3 . The method according to  claim 1 , wherein the Vitamin D 3  is substantially pure. 
     
     
         4 . The method according to  claim 1 , wherein the second composition consists essentially of about 100 mg to about 1,000 mg of heat shock proteins. 
     
     
         5 . The method according to  claim 1 , wherein:
 (i) about 150,000 IU of Vitamin D 3  is administered to the patient for about five days;   (ii) about 50,000 IU of Vitamin D 3  is administered to the patient weekly beginning on the 6 th  day of treatment; and   (iii) about 1,000 mg of heat shock proteins is administered to the patient daily beginning on the 6 th  day of treatment.   
     
     
         6 . The method according to  claim 1 , wherein:
 (i) about 5,000 IU of Vitamin D3; and   (ii) about 500 mg of heat shock proteins   
       is administered to the patient daily for about two weeks. 
     
     
         7 . The method according to  claim 1 , wherein the heat shock proteins is selected from the group consisting of twenty-seven kilo Dalton heat shock protein (Hsp27); sixty kilo Dalton heat shock protein (Hsp60); sixty-five kilo Dalton heat shock protein (Hsp65); seventy kilo Dalton heat shock protein (Hsp70); seventy-two kilo Dalton heat shock protein (Hsp72); and ninety kilo Dalton heat shock protein (Hsp90). 
     
     
         8 . The method according to  claim 1 , wherein the method of treating further comprises administering to the patient a composition comprising glutathione. 
     
     
         9 . The method according to  claim 8 , wherein the composition consists essentially of about 500 mg to about 1,000 mg of glutathione. 
     
     
         10 . The method according to  claim 1 , wherein the dosage form is an oral dosage form. 
     
     
         11 . The method according to  claim 10 , wherein the dosage form is a tablet, capsule or gel capsule. 
     
     
         12 . The method according to  claim 1 , wherein the disease is selected from the group consisting of chronic inflammation and chronic disease. 
     
     
         13 . The method according to  claim 12 , wherein the disease is selected from the group consisting of traumatic brain injury; concussion; congestive heart failure; coronary artery disease; heart attacks; stroke; chronic neurogenic disorders; arthritis; acute respiratory distress syndrome; community acquired pneumonia; ventilated associated pneumonia; dementia; Alzheimer's Disease; acute and chronic renal failure; multi-system organ failure; acute and chronic liver diseases, chronic obstructive pulmonary disease, acute and chronic pulmonary diseases, auto-immune diseases, cardiopulmonary arrest, and other diseases of aging. 
     
     
         14 . A kit comprising a first composition consisting essentially of Vitamin D 3  and a second composition consisting essentially of heat shock proteins, wherein the first composition and second composition are packaged for co-administration to a patient. 
     
     
         15 . The kit according to  claim 14 , wherein the first composition consists essentially of about 1,000 IU to about 150,000 IU of Vitamin D 3  and the second composition consists essentially of about 100 mg to about 1,000 mg of heat shock proteins. 
     
     
         16 . The kit according to  claim 14 , wherein the packaging consists of blister packs. 
     
     
         17 . The kit according to  claim 14 , wherein the blister packs are sold together and comprise blister packs containing the first composition and blister packs containing the second composition. 
     
     
         18 . The kit according to  claim 14 , wherein the blister packs contain both the first composition and the second composition paired together. 
     
     
         19 . The kit according to  claim 14 , wherein the blister packs containing said first composition and said second composition are advertised as more effective if co-administered. 
     
     
         20 . A method comprising providing the kit according to  claim 14  to patients.